| Full Name | Kalee Honeyfield |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 345 W A St, Fallon, Nevada |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760862304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | RP00008190 (New Mexico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kalee Honeyfield, 975 Kirman Ave, Reno, NV 89502-0993 Ph: () - | Kalee Honeyfield, 345 W A St, Fallon, NV 89406-2905 Ph: (775) 428-6161 |
News Archive
When infections occur in the body, stem cells in the blood often jump into action by multiplying and differentiating into mature immune cells that can fight off illness. But repeated infections and inflammation can deplete these cell populations, potentially leading to the development of serious blood conditions such as cancer.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.
XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.
› Verified 1 days ago
Christine Spradley, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Rio Vista Dr, Fallon, NV 89406 Phone: 775-423-3634 | |
Winston Ho, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2333 Reno Hwy, Fallon, NV 89406 Phone: 775-428-1710 | |
Mr. Steven David Sicherman, B.S. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 890 W Williams Ave, Fallon, NV 89406 Phone: 775-428-2340 | |
Jaime Cordoba, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 461 W Williams Ave, Fallon, NV 89406 Phone: 775-867-3700 Fax: 775-867-3747 | |
Donna Lyn Johnson, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2333 Reno Hwy, Fallon, NV 89406 Phone: 775-428-1710 Fax: 775-428-1767 | |
Madeleine F Wheeler, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2020 Reno Hwy, Fallon, NV 89406 Phone: 775-428-6409 Fax: 775-428-2826 | |
Chao Ran Li, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 801 E Williams Ave, Fallon, NV 89406 Phone: 775-423-3151 |